Literature DB >> 8191673

Comparison of two indwelling central venous access catheters in dogs undergoing fractionated radiotherapy.

K L Evans1, D D Smeak, C G Couto, A S Hammer, J S Gaynor.   

Abstract

Twenty dogs with neoplasms requiring multiple radiation treatments received either percutaneous vascular access catheters (PVACs; Cook, Bloomington, IN) or subcutaneous vascular access ports (SVAPs; Vascular-Access-Ports, Norfolk Medical Products, Inc., Skokie, IL); 10 dogs were entered in each group. All catheters were implanted and removed aseptically and the catheter tips were cultured during implant removal. Complications with PVACs included mild incisional swelling and redness and accidental severance or rupture of the catheter. Complications with SVAPs included incisional or port swelling, bruising or redness, hematoma formation, and pain. Ports in 4 of these dogs could not be used for 1 to 3 days after surgery because of swelling and pain. Surgical wound complications, when pooled for comparison, occurred significantly more frequently with the SVAPs (P = .023). Wound complications associated with both catheters were self-limiting and resolved within 7 days. Bacterial cultures were positive in two PVACs and four SVAP tips, however, none of these dogs had clinical signs of infection or sepsis. Although both types of indwelling catheters were functional in a clinical setting, PVACs were preferred to SVAPs for dogs undergoing radiation therapy because of decreased time for implantation and fewer overall complications.

Entities:  

Mesh:

Year:  1994        PMID: 8191673     DOI: 10.1111/j.1532-950x.1994.tb00458.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  1 in total

1.  Refinement of vascular access port placement in nonhuman primates: complication rates and outcomes.

Authors:  Melanie L Graham; Lucas A Mutch; Eric F Rieke; Michele Dunning; Elizabeth K Zolondek; Aaron W Faig; Bernhard J Hering; Henk-Jan Schuurman
Journal:  Comp Med       Date:  2010-12       Impact factor: 0.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.